Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Japan’s 1st Rituxan Biosimilar Boasts 13% Share: Sandoz Country Head
Jason Hoffe, president of the Japan unit of Sandoz, said on June 27 that the country’s first Rituxan (rituximab) biosimilar it rolled out in January together with local ally Kyowa Hakko Kirin grabbed a market share of some 13% five…
To read the full story
Related Article
- As Rituxan Biosimilar Enjoys Solid Start, Sandoz Japan Chief Says It’s Important to Be First to Market
August 9, 2018
- Kyowa Kirin Officially Announces Launch of Japan’s 1st Rituxan Biosimilar on Jan. 18
January 18, 2018
- Japan’s 1st Rituxan Biosimilar to Hit Shelves as Scheduled despite Patent Suit Filed
January 16, 2018
- Genentech Seeks to Block Rituxan Biosimilar Launch in Japan
January 10, 2018
- Japan’s 1st Rituxan Biosimilar to Arrive Soon, Sandoz Confident on Market Acquisition
November 29, 2017
- Japan Approves 1st Rituxan Biosimilar from Sandoz
September 28, 2017
BUSINESS
- Daiichi Sankyo’s I-DXd Filed in US for SCLC, Wins Priority Review
April 15, 2026
- Sanofi Japan Sales Rise 4.5% in 2025 as Dupixent Widens Label
April 15, 2026
- Eylea Biosimilar Supply Curbed amid Originator Disruption
April 14, 2026
- Novartis, JSH Begin Project to Address Regional Gaps in Hematology Care
April 14, 2026
- Nxera to Receive US$22.5 Million Milestone as Schizophrenia Drug Enters PII
April 14, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…